Composite
42%
Novelty
74%
Feasibility
43%
Impact
34%
Mechanistic
49%
Druggability
29%
Safety
26%
Confidence
31%

Mechanistic description

A more conjectural model is that APOE4-driven lipid remodeling changes ER membrane organization so that SCAP perceives cholesterol insufficiency at a given sterol mass. This is conceptually interesting and compatible with accessible-cholesterol biology, but currently lacks direct APOE4-specific evidence and remains below funding priority.

Evidence for (7)

  • SCAP responds to the accessible cholesterol fraction in ER membranes rather than simply total cholesterol mass.

  • APOE4 causes broad intracellular lipid-trafficking abnormalities that could plausibly alter membrane composition.

  • The ER cholesterol sensor SCAP promotes CARTS biogenesis at ER-Golgi membrane contact sites.

    PMID:33156328 2021 J Cell Biol
  • Dysfunction of cholesterol sensor SCAP promotes inflammation activation in THP-1 macrophages.

    PMID:29596892 2018 Exp Cell Res
  • Control of innate immunity and lipid biosynthesis in neurodegeneration.

    PMID:39156128 2024 Front Mol Neurosci
  • SCAP, an ER sensor that regulates cell cholesterol.

    PMID:12361593 2002 Dev Cell
  • Assaying Sterol-Regulated ER-to-Golgi Transport of SREBP Cleavage-Activating Protein Using Immunofluorescence Microscopy.

    PMID:36512249 2023 Methods Mol Biol

Evidence against (3)

  • No direct evidence links APOE4 to a shifted SCAP cholesterol threshold in ER membranes.

  • Apparent changes in accessible cholesterol could instead reflect altered sterol mass, probe artifacts, or generalized membrane stress.

  • Interventions such as SOAT1/ACAT1 modulation are broad and may perturb lipid droplets, ER stress responses, and myelination.